Zydus, Roche legal conflict underscores need for affordable breast cancer treatments in India, Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com

​Earlier, Roche lodged a complaint to the Drugs Controller General of India (DGCI), alleging Zydus might have procured the reference drug from an unauthorised supply chain to conduct the clinical trials and now for a formulation patent infringement. However, Roche does not currently hold a product patent for pertuzumab in India. It is a fact that Zydus’ Sigrima was approved by the Central Drugs Standard Control Organization (CDSCO) in April 2024 and permitted for sale in June 2024., ​Earlier, Roche lodged a complaint to the Drugs Controller General of India (DGCI), alleging Zydus might have procured the reference drug from an unauthorised supply chain to conduct the clinical trials and now for a formulation patent infringement. However, Roche does not currently hold a product patent for pertuzumab in India. It is a fact that Zydus’ Sigrima was approved by the Central Drugs Standard Control Organization (CDSCO) in April 2024 and permitted for sale in June 2024., , Read More